SOHO 2024 | The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL
Farhad Ravandi
• 7 Sep 2024
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the incorporation of venetoclax into the hyper-CVAD-nelarabine and pegylated asparaginase regimen for treating T-cell acute lymphoblastic leukemia (T-ALL). Dr Ravandi highlights the benefits of combining these agents, particularly in early precursor T-ALL (ETP-ALL) and patients with persistent measurable residual disease (MRD). This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
